Fungemia with Compromised Host Resistance

A Study of 70 Cases

  1. ROBERT C. YOUNG, M.D., F.A.C.P.;
  2. JOHN E. BENNETT, M.D., F.A.C.P.;
  3. GLENN W. GEELHOED, M.D.; and
  4. ARTHUR S. LEVINE, M.D.
  1. Bethesda, Maryland

    Abstract

    Seventy patients with antemortem fungemia were studied. The findings and subsequent course of the patients allowed these episodes of fungemia to be related to disseminated fungal infection (44 patients), transient catheter-induced fungemia (8 patients), or clinically insignificant fungemia (18 patients). Candida fungemias were associated with disseminated mycosis when the patients were immunosuppressed, leukopenic, grew Candida organisms from three or more other sites, or did not have a contaminated intravenous catheter. Noncandida fungemias were associated with disseminated fungal infection when the patients had multiple other positive sites, grew fungus out of more than one blood culture, and had fungemias with recognized pathogens. Sixty-three percent of the patients had either autopsy-proved or clinically diagnosed disseminated mycoses. Fungemia in patients with compromised host resistance, especially lymphoreticular or hematopoietic malignancies, is frequently associated with disseminated fungal infection.

    Article and Author Information

    • ▸From the Medicine, Surgery, and Pediatric Oncology Branches, National Cancer Institute; and the Laboratory of Clinical Investigation, National Institute of Allergy and Infectious Diseases; National Institutes of Health, Bethesda, Maryland.

    • ▸Requests for reprints should be addressed to Robert C. Young, M.D., Medicine Branch, National Cancer Institute, Bethesda, MD 20014.

      • Received October 1, 1973.
      • Accepted February 15, 1974.
    « Previous | Next Article »Table of Contents